无惧外部扰动，创新药逆势上涨，恒生生物科技指数翻红

Core Viewpoint - The expectation for a Federal Reserve interest rate cut in December has diminished, leading to significant adjustments in key indices of A-shares and Hong Kong stocks, while the Hang Seng Biotechnology Index experienced a rapid rebound [1] Group 1: Market Performance - The Hang Seng Biotechnology Index, launched by the Hang Seng Index Company in 2019, reflects the overall performance of the biotechnology sector in the Hong Kong stock market [1] - The index not only focuses on innovative drugs but also incorporates upstream CXO companies, providing a more comprehensive view of the entire innovative drug industry chain [1] - Notable stocks leading the index's performance include Kingsoft Biotech, JD Health, Hansoh Pharmaceutical, and 3SBio [1] Group 2: Derivative Products - The Hong Kong Stock Exchange announced plans to launch futures for the Hang Seng Biotechnology Index on October 14, 2023, enhancing its expanding ecosystem of derivative products [1] - The new futures contract is set to begin trading on November 28, 2025, offering investors precise risk management tools [1] - The Hang Seng Biotechnology Index is the only index in the Hong Kong pharmaceutical and healthcare sector that has index futures available [1]